MENS

Jyong Biotech Ltd.

Price Chart

Latest Quote

$1.74

+0.10 (+6.10%)

Current Price

Previous Close	$1.64
Open	$1.63
Day High	$1.77
Day Low	$1.62
Volume	308,502

Fetched: 2026-06-25T01:29:20

Stock Information

Shares Outstanding	74.23M
Total Debt	$18.55M
Cash Equivalents	$1.18M
Net Income	$-4.67M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$132.29M
EPS (TTM)	$-0.06
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$146.54M
Income	$-4.67M
Book/sh	$-0.34
Cash/sh	$0.02
Employees	27

Financial Ratios

Quick Ratio	0.03
Current Ratio	0.45

Returns & Margins

ROA

-12.01%

Ownership

Insider Ownership	62.20%
Institutional Ownership	0.71%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

-5.18

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$1.86
SMA50	$2.06
SMA200	$17.44
RSI	27.27
ATR	0.1871

Shares Float	26.94M
Short Float	0.61%
Short Ratio	4.91
Rel Volume	2.33

Performance History

Week	+8.75%
Month	-19.07%
Quarter	-13.00%
6 Months	-45.20%
YTD	-48.97%
Year	-76.86%
10 Years	-82.79%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-24	$1.74	308,502
2026-06-23	$1.64	230,200
2026-06-22	$1.59	80,500
2026-06-18	$1.56	120,600
2026-06-17	$1.60	182,100
2026-06-16	$1.60	189,900
2026-06-15	$1.60	269,300
2026-06-12	$1.58	199,800
2026-06-11	$1.71	236,100
2026-06-10	$1.72	210,100
2026-06-09	$1.81	105,200
2026-06-08	$2.00	36,200
2026-06-05	$2.02	58,900
2026-06-04	$2.10	50,000
2026-06-03	$2.09	53,200
2026-06-02	$2.16	125,100
2026-06-01	$2.06	79,900
2026-05-29	$2.20	27,900
2026-05-28	$2.25	41,500
2026-05-27	$2.16	38,900
2026-05-26	$2.17	57,900

About Jyong Biotech Ltd.

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

📰 Latest News

CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop

Simply Wall St. • 2026-02-10T10:46:58Z

Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8

TipRanks • 2025-11-21T13:45:58Z

Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility

Simply Wall St. • 2025-11-21T06:11:25Z

Evaluating Jyong Biotech (NasdaqGM:MENS): What Recent Price Moves Reveal About Its Current Valuation

Simply Wall St. • 2025-09-14T12:33:42Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$2,539,000	$1,035,000	$757,000	$765,000
Total Expenses	$2,607,000	$2,056,000	$2,797,000	$2,829,000
Other Income Expense	$-135,000	$65,000	$-902,000	$-3,041,000
Other Non Operating Income Expenses	$-135,000	$65,000	$-902,000	$-3,041,000
Net Non Operating Interest Income Expense	$-1,929,000	$-1,028,000	$-701,000	$-760,000
Interest Expense Non Operating	$2,539,000	$1,035,000	$757,000	$765,000
Operating Expense	$2,607,000	$2,056,000	$2,797,000	$2,829,000
Selling And Marketing Expense	$45,000	$44,000	$47,000	$47,000
General And Administrative Expense	$1,749,000	$1,085,000	$1,679,000	$1,492,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Net Interest Income	$-1,929,000	$-1,028,000	$-701,000	$-760,000
Interest Income	$610,000	$7,000	$56,000	$5,000
Normalized Income	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Net Income From Continuing And Discontinued Operation	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Total Operating Income As Reported	$-2,607,000	$-2,056,000	$-2,797,000	$-2,829,000
Net Income Common Stockholders	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Net Income	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Net Income Including Noncontrolling Interests	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Net Income Continuous Operations	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Pretax Income	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Interest Income Non Operating	$610,000	$7,000	$56,000	$5,000
Operating Income	$-2,607,000	$-2,056,000	$-2,797,000	$-2,829,000
Per Share
Diluted EPS	-	$-0.04	$-0.06	$-0.09
Basic EPS	-	$-0.04	$-0.06	$-0.09
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-2,032,000	$-1,864,000	$-3,516,000	$-5,742,000
Reconciled Depreciation	$100,000	$120,000	$127,000	$123,000
EBITDA (Bullshit earnings)	$-2,032,000	$-1,864,000	$-3,516,000	$-5,742,000
EBIT	$-2,132,000	$-1,984,000	$-3,643,000	$-5,865,000
Diluted NI Availto Com Stockholders	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Tax Provision	$0	$0	$0	$0
Research And Development	$813,000	$927,000	$1,071,000	$1,290,000
Selling General And Administration	$1,794,000	$1,129,000	$1,726,000	$1,539,000
Other Gand A	$1,749,000	$1,085,000	$1,679,000	$1,492,000
Diluted Average Shares	-	$76,027,667	$76,027,667	$76,027,667
Basic Average Shares	-	$76,027,667	$76,027,667	$76,027,667

Fetched: 2026-06-23

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-24,906,000	$-36,519,000	$-34,073,000	$-29,631,000
Total Assets	$20,778,000	$6,366,000	$8,248,000	$8,745,000
Total Non Current Assets	$5,236,000	$6,160,000	$6,409,000	$6,282,000
Other Non Current Assets	$2,082,000	$2,040,000	$2,144,000	$7,000
Non Current Deferred Assets	$0	$934,000	$721,000	$276,000
Current Assets	$15,542,000	$206,000	$1,839,000	$2,463,000
Other Current Assets	$854,000	$105,000	$97,000	$95,000
Restricted Cash	$3,000	$3,000	$1,565,000	$1,556,000
Receivables	$13,510,000	$0	-	-
Loans Receivable	$13,510,000	$0	-	-
Cash Cash Equivalents And Short Term Investments	$1,175,000	$98,000	$177,000	$812,000
Cash And Cash Equivalents	$1,175,000	$98,000	$177,000	$718,000
Cash Equivalents	$1,174,000	$97,000	$176,000	$715,000
Cash Financial	$1,000	$1,000	$1,000	$3,000
Debt
Net Debt	$17,267,000	$17,862,000	$16,315,000	$13,248,000
Total Debt	$18,549,000	$18,135,000	$16,691,000	$14,251,000
Long Term Debt And Capital Lease Obligation	$10,186,000	$10,694,000	$8,589,000	$6,433,000
Long Term Debt	$10,160,000	$10,678,000	$8,520,000	$6,318,000
Current Debt And Capital Lease Obligation	$8,363,000	$7,441,000	$8,102,000	$7,818,000
Current Debt	$8,282,000	$7,282,000	$7,972,000	$7,648,000
Other Current Borrowings	$8,282,000	$7,282,000	$7,972,000	$7,648,000
Liabilities
Total Liabilities Net Minority Interest	$45,684,000	$42,885,000	$42,321,000	$38,376,000
Total Non Current Liabilities Net Minority Interest	$10,874,000	$30,758,000	$28,063,000	$25,469,000
Other Non Current Liabilities	$60,000	$19,436,000	$18,846,000	$18,408,000
Tradeand Other Payables Non Current	$0	$0	$0	$0
Current Liabilities	$34,810,000	$12,127,000	$14,258,000	$12,907,000
Other Current Liabilities	$3,481,000	$3,326,000	$4,994,000	$4,218,000
Payables And Accrued Expenses	$22,966,000	$1,360,000	$1,162,000	$871,000
Interest Payable	$320,000	$343,000	$282,000	$230,000
Payables	$70,000	$44,000	$23,000	$8,000
Accounts Payable	$2,000	$3,000	$2,000	$4,000
Equity
Common Stock Equity	$-24,906,000	$-36,519,000	$-34,073,000	$-29,631,000
Total Equity Gross Minority Interest	$-24,906,000	$-36,519,000	$-34,073,000	$-29,631,000
Stockholders Equity	$-24,906,000	$-36,519,000	$-34,073,000	$-29,631,000
Gains Losses Not Affecting Retained Earnings	$682,000	$1,121,000	$548,000	$590,000
Other Equity Adjustments	$682,000	$1,121,000	$548,000	$590,000
Retained Earnings	$-37,751,000	$-33,080,000	$-30,061,000	$-25,661,000
Other
Treasury Shares Number	$1,794,000	-	-	-
Ordinary Shares Number	$74,233,667	$76,027,667	$76,027,667	$76,027,667
Share Issued	$76,027,667	$76,027,667	$76,027,667	$76,027,667
Tangible Book Value	$-24,906,000	$-36,519,000	$-34,073,000	$-29,631,000
Invested Capital	$-6,464,000	$-18,559,000	$-17,581,000	$-15,665,000
Working Capital	$-19,268,000	$-11,921,000	$-12,419,000	$-10,444,000
Capital Lease Obligations	$107,000	$175,000	$199,000	$285,000
Total Capitalization	$-14,746,000	$-25,841,000	$-25,553,000	$-23,313,000
Treasury Stock	$16,366,000	$16,366,000	$16,366,000	$16,366,000
Additional Paid In Capital	$28,528,000	$11,805,000	$11,805,000	$11,805,000
Capital Stock	$1,000	$1,000	$1,000	$1,000
Common Stock	$1,000	$1,000	$1,000	$1,000
Dueto Related Parties Non Current	$628,000	$628,000	$628,000	$628,000
Long Term Capital Lease Obligation	$26,000	$16,000	$69,000	$115,000
Current Capital Lease Obligation	$81,000	$159,000	$130,000	$170,000
Current Accrued Expenses	$22,896,000	$1,316,000	$1,139,000	$863,000
Dueto Related Parties Current	$68,000	$41,000	$21,000	$4,000
Net PPE	$3,154,000	$3,186,000	$3,544,000	$5,999,000
Accumulated Depreciation	$-1,745,000	$-1,576,000	$-1,562,000	$-1,427,000
Gross PPE	$4,899,000	$4,762,000	$5,106,000	$7,426,000
Leases	$146,000	$140,000	$150,000	$150,000
Construction In Progress	$140,000	$135,000	$139,000	$144,000
Other Properties	$891,000	$926,000	$1,003,000	$3,333,000
Machinery Furniture Equipment	$139,000	$133,000	$143,000	$142,000
Buildings And Improvements	$2,588,000	$2,476,000	$2,651,000	$2,641,000
Land And Improvements	$995,000	$952,000	$1,020,000	$1,016,000
Properties	$0	$0	$0	$0
Other Short Term Investments	-	-	$0	$94,000
Line Of Credit	-	-	-	$7,169,000

Fetched: 2026-06-23

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-3,041,000	$-3,624,000	$-2,601,000	$-3,217,000
Operating Activities
Operating Cash Flow	$-3,041,000	$-3,624,000	$-2,601,000	$-2,971,000
Cash Flow From Continuing Operating Activities	$-3,041,000	$-3,624,000	$-2,601,000	$-2,971,000
Operating Gains Losses	$-3,000	-	-	-
Investing Activities
Investing Cash Flow	$-13,507,000	$0	$95,000	$1,392,000
Cash Flow From Continuing Investing Activities	$-13,507,000	$0	$95,000	$1,392,000
Net Other Investing Changes	$-13,510,000	-	-	-
Capital Expenditure	-	-	-	$-246,000
Financing Activities
Issuance Of Capital Stock	$17,771,000	$0	$0	-
Financing Cash Flow	$17,633,000	$1,990,000	$2,028,000	$3,333,000
Cash Flow From Continuing Financing Activities	$17,633,000	$1,990,000	$2,028,000	$3,333,000
Net Other Financing Charges	$-114,000	$-213,000	$-445,000	$-276,000
Net Common Stock Issuance	$17,771,000	$0	$0	-
Common Stock Issuance	$17,771,000	$0	$0	-
Other
Repayment Of Debt	$-24,496,000	$-9,465,000	$-9,356,000	$-8,668,000
Issuance Of Debt	$24,472,000	$11,668,000	$11,829,000	$12,277,000
Interest Paid Supplemental Data	$337,000	$223,000	$104,000	$162,000
Income Tax Paid Supplemental Data	$0	$0	$0	$0
End Cash Position	$1,178,000	$101,000	$1,742,000	$2,274,000
Beginning Cash Position	$101,000	$1,742,000	$2,274,000	$551,000
Effect Of Exchange Rate Changes	$-8,000	$-7,000	$-54,000	$-31,000
Changes In Cash	$1,085,000	$-1,634,000	$-478,000	$1,754,000
Net Issuance Payments Of Debt	$-24,000	$2,203,000	$2,473,000	$3,609,000
Net Short Term Debt Issuance	$160,000	$-153,000	$690,000	$2,963,000
Short Term Debt Payments	$-22,936,000	$-9,394,000	$-9,113,000	$-8,377,000
Short Term Debt Issuance	$23,096,000	$9,241,000	$9,803,000	$11,340,000
Net Long Term Debt Issuance	$-184,000	$2,356,000	$1,783,000	$646,000
Long Term Debt Payments	$-1,560,000	$-71,000	$-243,000	$-291,000
Long Term Debt Issuance	$1,376,000	$2,427,000	$2,026,000	$937,000
Net Investment Purchase And Sale	$3,000	$0	$95,000	$1,638,000
Sale Of Investment	$16,873,000	$0	$95,000	$1,930,000
Purchase Of Investment	$-16,870,000	$0	$0	$-292,000
Change In Working Capital	$20,735,000	$-1,486,000	$1,118,000	$2,937,000
Change In Other Current Liabilities	$-93,000	$-1,647,000	$826,000	$2,974,000
Change In Payables And Accrued Expense	$21,577,000	$169,000	$294,000	$-205,000
Change In Accrued Expense	$21,578,000	$168,000	$296,000	$-177,000
Change In Payable	$-1,000	$1,000	$-2,000	$-28,000
Change In Account Payable	$-1,000	$1,000	$-2,000	$-28,000
Change In Prepaid Assets	$-749,000	$-8,000	$-2,000	$168,000
Other Non Cash Items	$-19,202,000	$761,000	$554,000	$599,000
Depreciation Amortization Depletion	$100,000	$120,000	$127,000	$123,000
Depreciation And Amortization	$100,000	$120,000	$127,000	$123,000
Depreciation	$100,000	$120,000	$127,000	-
Gain Loss On Investment Securities	$-3,000	-	-	-
Net Income From Continuing Operations	$-4,671,000	$-3,019,000	$-4,400,000	$-6,630,000
Net PPE Purchase And Sale	-	-	$0	$-246,000
Purchase Of PPE	-	-	$0	$-246,000
Change In Other Current Assets	-	-	-	$0

Fetched: 2026-06-23